Business
Rigel acquires first-ever PROTAC approval with USD 70 million Veppanu deal from Arvinas and Pfizer
Rigel Pharmaceuticals (Nasdaq: RIGL) has closed its exclusive global license for VEPPANU (vepdegestrant), paying USD 70 million upfront to Arvinas (Nasdaq:...
Triveni Bio secures USD 65 million to expand first-in-class bispecific antibody into atopic dermatitis
Watertown, Massachusetts-based Triveni Bio Inc., a clinical-stage biotechnology company developing antibody therapies for immunological and inflammatory...
Bayer completes USD 2.45b purchase of Perfuse for first-in-class endothelin antagonist
Bayer has completed its acquisition of Perfuse Therapeutics, gaining full global rights to PER-001, a first-in-class sustained-release endothelin receptor...
Zydus expands US oncology footprint with USD 166 million Assertio acquisition
India-based Zydus Lifesciences (NSE: ZYDUSLIFE) completed its acquisition of Lake Forest, Illinois-based Assertio Holdings, Inc. (Nasdaq: ASRT) on June 16,...
Innoviva expands antibiotic Xacduro into emerging markets with Dr. Reddy's partnership
Innoviva's only FDA-approved antibiotic for carbapenem-resistant Acinetobacter baumannii is heading to some of the world's most resistance-burdened hospital...
Cystic Fibrosis Foundation backs SpliSense's Phase IIb push with USD 13m for orphan CF mutation
Israel-based SpliSense announced a funding agreement with the Cystic Fibrosis Foundation under which the Foundation will provide up to USD 13 million to...
SSY Group pivots to renal therapeutics via license to Opterion's osmotic agent
SSY Group's subsidiary has signed a letter of intent to license OPT101, a novel non-glucose osmotic agent for peritoneal dialysis, from Switzerland-based...
AviadoBio converts neurology-only gene therapy license into universal platform across all human diseases
UK-based AviadoBio has expanded its exclusive license agreement with King's College London, converting a neurology-only platform license into a universal IP...
Lilly deepens pain strategy with acquisition of MNK inhibitor developer 4E Therapeutics
Eli Lilly's acquisition of Austin, Texas-based 4E Therapeutics, Inc. adds a first-in-class oral MNK inhibitor to its expanding non-opioid pain pipeline,...
Dimerix adds China, SE Asia partner for Phase III CCR2 antagonist with USD 340m Everest deal
Australia-based Dimerix Limited (ASX: DXB) has completed its fifth and final major territorial licensing transaction for its Phase III kidney disease...
Cellares raises USD 327m to scale automated cell therapy manufacturing globally
South San Francisco-based Cellares has extended its Series D financing to USD 327 million following a USD 50 million growth equity investment from Prime...
Alvotech raises USD 152m to advance biosimilar pipeline and shore up balance sheet
Iceland-based Alvotech (Nasdaq: ALVO) announced the pricing of a combined underwritten public offering and concurrent private placement totaling...
Aplagon expands APAC into kidney disease complication with EUR 4.8m financing round
Finland-based Aplagon Oy has closed a EUR 4.8 million (approximately USD 5.6 million) financing round to fund a new Phase II clinical programme in...
Lonza's dual-payload ADC platform advances to clinic with Antharis gastrointestinal cancer deal
Lonza (SIX: LONN) has granted San Diego-based Antharis Therapeutics, Inc. an exclusive, target-specific license to its proprietary dual-payload ADC platform...
Porosome Therapeutics opens India partnership to validate secretory dysfunction theory across six diseases
Boston-based Porosome Therapeutics, Inc. has entered a drug development partnership with India's Council of Scientific and Industrial Research (CSIR), the...
The AllSci Brief
Systematic R&D and deal news. Daily.